SCHEMBL5218869

SCHEMBL5218869

CCCCn1c(-c2ccccc2)nc(-c2ccc(OC)cc2)c1CN(CCC(C)C)Cc1ccc(C(N)=O)c(CC(=O)O)c1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.37
MC4R P32245 1/20 0.36
HDAC1 Q13547 1/20 0.36
NR1H3 Q13133 2/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.34
GNRHR P30968 2/20 0.34
CNR2 P34972 1/20 0.33
TSPO P30536 1/20 0.33
PARP1 P09874 2/20 0.33
ATM Q13315 1/20 0.33
CTSD P07339 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PPARG P37231 1/20 0.33
BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633347 0.94 C5AR1 (0.40) C5AR1HDAC1NR1H3PTGDR2GNRHR
SCHEMBL648873 0.91 MC4R (0.37) C5AR1MC4RHDAC1NR1H3PARP1
SCHEMBL1913052 0.89 C5AR1 (0.37) C5AR1MC4RHDAC1NR1H3GNRHR
SCHEMBL651825 0.87 C5AR1 (0.39) C5AR1HDAC1NR1H3ATMTDP1
SCHEMBL5633847 0.87 C5AR1 (0.53) C5AR1GNRHRTDP1PPARG
SCHEMBL5225249 0.86 C5AR1 (0.38) C5AR1HDAC1PTGDR2GNRHRCNR2
SCHEMBL650787 0.85 C5AR1 (0.41) C5AR1HDAC1TDP1PPARG
SCHEMBL648586 0.84 C5AR1 (0.39) C5AR1TSPOPARP1PPARGBCHE
SCHEMBL5218884 0.84 NR1H3 (0.38) C5AR1MC4RHDAC1NR1H3TSPO
SCHEMBL651426 0.83 C5AR1 (0.38) C5AR1HDAC1PARP1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed